Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

Fig. 2

Pharmacological inhibition of Bcr-Abl and TNFα reduces leukemic progenitor cell growth. a Lin SCLtTA/Bcr-Abl BM cells were treated for 72 h with 500 μg/ml IFX, 100 nM nilotinib and the combination of both agents. 1000 treated cells were seeded per ml into methylcellulose. b 5000 cells/ml from (a) were used for re-plating. c Lin BM cells from SCLtTA/Bcr-Abl mice were subjected to MP6-XT22 (2 μg/ml), 100 nM nilotinib and the combination of both agents in the absence or in the presence of 0.05 ng/ml TNFα for 72 h. 1000 treated cells/ml cells were seeded into methylcellulose d 1 × 104 cells/ml from (c) were used for re-plating. e HoxB8 immortalized progenitor BM cells from SCLtTA/Bcr-Abl mice were treated with MP6-XT22 (2 μg/ml), 100 nM nilotinib and the combination of both agents in the absence or presence of 0.05 ng/ml TNFα for 72 h. 2000 treated cells/ml were seeded into methylcellulose. f apoptosis was evaluated by AnnexinV/7AAD staining (light grey: Annexin V pos; dark grey: Annexin V/7AAD pos) and g proliferation was assessed by cell counting using 32D:Bcr-Abl cells that were subjected to MP6-XT22 (2 μg/ml), 100 nM nilotinib or the combination of both agents, in the absence or in the presence of 0.05 ng/ml TNFα. (n = 3 for each treatment, *p < 0.05, **p < 0.01, ***p < 0.001)

Back to article page